Delving into the Latest Updates on IMMUXELL BIOTECH LTD. with Synapse

Overview

Tags

Neoplasms

Endocrinology and Metabolic Disease

Digestive System Disorders

TCR therapy

TCR fusion protein

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

TCR therapy	2
Small molecule drug	1
TCR fusion protein	1

Top 5 Target	Count

KRAS(GTPase KRas)	2
12/15-LOX(Arachidonate 15-lipoxygenase)	1
CD3 x KRAS	1

This is a single-arm, single-center, open-label clinical study aimed at evaluating the safety and efficacy of IX001 TCR-T (T cell receptor-engineered T-Cell) injection in patients with advanced pancreatic cancer and colorectal cancer induced by KRAS (Kirsten Rat Sarcoma Viral Oncogene) mutations. A total of 6-18 evaluable patients are planned to be enrolled. The study will include 4 dose groups, using a '3+3' dose escalation design.

Start Date01 Jul 2024

Sponsor / Collaborator

Shanghai Pudong Hospital

[+1]

100 Clinical Results associated with IMMUXELL BIOTECH LTD.

Login to view more data

0 Patents (Medical) associated with IMMUXELL BIOTECH LTD.

Login to view more data

1

Literatures (Medical) associated with IMMUXELL BIOTECH LTD.

15 Oct 2024·Analytical Chemistry

DEPICT-seq: Single-Cell Transcriptomic Analysis of Rare Cell Subsets Isolated via Nucleic Acid Cytometry

Article

Author: Bao, Kaixuan ; Liu, Tiemin ; Zhang, Jingwei ; Hu, Hong-min ; Jiang, Xiaochun

The ability to dive deep into specific rare cell populations is critical for understanding tissue physiology and pathology across various biological domains. As single-cell RNA-seq flourishes, many newly discovered cell subtypes are defined by their transcriptomic markers. However, our ability to retrieve and analyze cells based on their nucleic acid markers remains underdeveloped. Here, we present Double Emulsion PCR-Initiated Cell sorting and Transcriptomic Sequencing (DEPICT-seq), a high-throughput droplet nucleic acid cytometry method that integrates batch cell fixation for cellular information preservation, double emulsion digital PCR-based cell sorting to target nucleic acid markers of interest, and in-depth full-length transcriptomic analyses at single-cell resolution. We utilize DEPICT-seq to isolate and characterize T cell receptor (TCR)-engineered T cells within a mixed population and also demonstrate a variation of the workflow by incorporating an RNase H-dependent PCR step to enrich full-length TCR sequences for paired single-cell TCR sequencing and transcriptomic profiling.

100 Deals associated with IMMUXELL BIOTECH LTD.

Login to view more data

100 Translational Medicine associated with IMMUXELL BIOTECH LTD.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

IND Approval

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IX001 TCR-T cells ( KRAS )	KRAS Mutant Pancreatic Cancer More	IND Approval
TCR-ICE (IMMUXELL) ( CD3 x KRAS )	Neoplasms More	Preclinical
TCR-NK (IMMUXELL) ( KRAS )	Neoplasms More	Preclinical
ALOX15 inhibitor (Guangdong Medical University) ( 12/15-LOX )	Pancreatic Ductal Adenocarcinoma More	Preclinical
KRAS G12V(Guangzhou Bintie) ( KRAS )	Solid tumor More	Preclinical